Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Barcelona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Active, closed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238Haemophilia A, Haemophilia A With Inhibitors

Novo Nordisk A/S

Phase 3

451

Barcelona, Esplugues Llobregat, Madrid, Málaga

2023-02-13

Recruiting

Effects of the Application of PIOMI in the Oral Feeding of Premature

NCT06395298Dysphagia, Disorder; Feeding, Newborn, Premature

Fundació Sant Joan de Déu

Not applicable

Barcelona

2023-02-13

Recruiting

Prevalence and Clinical Implications of HPV Infection in Male IBD Patients

NCT05911750HPV Infection, Dysplasia Anus, Oral Cavity Disease

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

384

Barcelona

2023-02-12

Active, closed

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899High-risk Large B-cell Lymphoma (LBCL)

DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin

Kite, A Gilead Company

Phase 3

300

Barcelona, Madrid, Salamanca, Santander, Seville, Valencia

2023-02-10

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Madrid, El Palmar, Pamplona, Valencia

2023-02-08

Recruiting

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

NCT05496998Mitral Regurgitation

Medtronic Cardiovascular

Not applicable

400

Barcelona, Madrid, Oviedo, Vigo

2023-02-07

Active, closed

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

226

Barcelona, Madrid, Murcia, Salamanca, Seville

2023-02-03

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Barakaldo, Badajoz, Barcelona, Burgos, Madrid, Seville, Valencia

2023-02-03

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

NCT05982093Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer

DrugsElacestrant·Tamoxifen

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Vilanova, El Palmar, Badajoz, Barcelona, Cáceres, Madrid

2023-02-03

Recruiting

Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units

NCT05686850Post Extubation Respiratory Failure

Poitiers University Hospital

Not applicable

670

Barcelona, L'Hospitalet de Llobregat, Oviedo, Toledo

2023-02-02

Active, closed

A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9

NCT05723835SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugSomapacitan

Novo Nordisk A/S

Phase 3

Barcelona

2023-02-01

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

NCT05679895T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma

OneChain Immunotherapeutics

Phase 1

Barcelona

2023-01-31

Active, closed

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

NCT05599061Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease

Fundación EPIC

Not applicable

609

L'Hospitalet de Llobregat, A Coruña, Albacete, Alicante, Badalona, Barcelona, Cadiz, Castellon

2023-01-30

Active, closed

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013Polycythemia Vera

Silence Therapeutics plc

Phase 1/2

Barcelona, Madrid

2023-01-26

Active, closed

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304Ischemic Stroke, Systemic Embolism

AtriCure, Inc.

Not applicable

6,573

Barcelona, Madrid

2023-01-25

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

A Coruña, Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Valencia

2023-01-24

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258Autosomal Recessive Polycystic Kidney (ARPKD)

DrugTolvaptan

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

Esplugues de Llobregat, Sabadell, Barcelona, Seville

2023-01-23

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Valencia

2023-01-23

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Madrid, Valencia, Barcelona

2023-01-19

Active, closed

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361Multifocal Motor Neuropathy (MMN)

DrugEmpasiprubart

argenx

Phase 2

Barcelona, Valencia

2023-01-18

Recruiting

Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction

NCT05038462Fetal Growth Retardation, Intrauterine Growth Restriction

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Not applicable

304

Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat

2023-01-18

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Barcelona, Elche(Alicante), L'Hospitalet de Llobregat, Madrid, Santander

2023-01-16

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Badalona, Santander, Barcelona, Oviedo, Granada, Lugo, Madrid, Seville

2023-01-16

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Fuenlabrada, Barcelona, Girona, Huelva, Madrid

2023-01-16

Recruiting

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

NCT05916755Triple Negative Breast Cancer

DrugPembrolizumab

Vall d'Hebron Institute of Oncology

Observational

100

Barcelona

2023-01-13

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Barcelona, Madrid, Santander

2023-01-12

Active, closed

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

513

Mérida, Barcelona, Bilbao, Santander, Cordoba, Seville, Valencia, Valladolid

2023-01-12

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valenica, Zaragoza

2023-01-11

Recruiting

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

DrugsElacestrant·Exemestane·Everolimus·Abemaciclib

Ellipses Pharma

Phase 1/2

Usera, Barcelona, Madrid

2023-01-11

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Badalona, Córdoba, Barcelona, Madrid, Valencia

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Badalona, Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, San Cristóbal de La Laguna, Valencia, Granada

2023-01-10

Recruiting

Alleviant ALLAY-HF Study

NCT05685303Heart Failure

Alleviant Medical, Inc.

Not applicable

700

Barcelona, Cadiz, Madrid, Salamanca, Valencia

2023-01-10

Active, closed

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241IgG4 Related Disease

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 3

194

Madrid, Barcelona, Seville

2023-01-09

Active, closed

Influence of the Different Types of Tibial Fixation in the Reconstruction of the Anterior Cruciate Ligament of the Knee: Osseous Integration, Ligament Maturation and Clinical Results.

NCT07753707ACL - Anterior Cruciate Ligament Rupture

Institut Català de Traumatologia i Medicina de l'Esport

Not applicable

111

Barcelona

2023-01-07

Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis

DrugDapansutrile

Olatec Therapeutics, Inc.

Phase 2/3

300

Alicante, Barcelona, Madrid

2023-01-06

Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm

DrugSTAR0602

Marengo Therapeutics, Inc.

Phase 1/2

366

Barcelona, Madrid, Valencia

2023-01-04

Active, closed

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

DrugGSK4532990

GlaxoSmithKline

Phase 2

284

Barcelona, Madrid, Málaga, Sabadell Barcelona, Santander, Seville, Vigo

2023-01-02

Recruiting

No-biopsy Approach in Celiac Disease: Cut-off Points for IgA Anti-tissue Transglutaminase Assays

NCT05983978Celiac Disease

Instituto de Investigación Hospital Universitario La Paz

Observational

150

Terrassa, Lugo, Madrid, Barcelona

2023-01-02

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

NCT05306041HER2-positive Breast Cancer

DrugsPhesgo·Inavolisib

GBG Forschungs GmbH

Phase 2

170

Barcelona, Granada, Lleida, Madrid, Murcia, Palma de Mallorca, Santander, Seville

2023-01-02

Active, closed

Adaptation Plan for Culturally Competent Care (PAACI) in the Acute Psychiatric Unit.

NCT06879093Mental Disorders, Cultural Competency, Psychiatric Hospitalization

Parc de Salut Mar

Observational

200

Barcelona

2023-01-01

Active, closed

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673Non-Clear Cell Renal Cell Carcinoma

DrugsSunitinib Malate·Zanzalintinib·Sunitinib·Opdivo

Exelixis

Phase 3

317

Palma de Mallorca, Majadahonda, Barcelona, Córdoba, Girona, Madrid, Málaga, Oviedo

2023-01-01

Recruiting

International Leukemia Target Board

NCT05270096Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy

Princess Maxima Center for Pediatric Oncology

Observational

600

Barcelona

2022-12-31

Active, closed

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

Barcelona, Murcia

2022-12-30

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Barcelona, Valencia, Bilbao, Córdoba, Granada, Madrid, Málaga

2022-12-29

Active, closed

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642Chronic Obstructive Pulmonary Disease (COPD)

DrugAstegolimab

Hoffmann-La Roche

Phase 3

1,290

Palma de Mallorca, Ponferrada, Torrejón de Ardoz, Benalmádena Costa, Barcelona, Seville, Valencia

2022-12-29

Active, closed

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 2

Barcelona, Madrid, Majadahonda, Pontevedra, Valladolid, Zaragoza

2022-12-29

By invitation

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 2/3

150

Barcelona, Madrid

2022-12-28

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

A Coruña, Almería, Barcelona, Cabra, Granada, Jaén, León, Madrid

2022-12-27

Recruiting

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

NCT05835609Patients With Advanced Solid Tumors

PharmaMar

Phase 1

Barcelona, Madrid

2022-12-23

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

NCT04953910Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugDecitabine

Taiho Oncology, Inc.

Phase 1

Barcelona, La Rioja, Lleida, Madrid, Murcia, Valencia

2022-12-23

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Barcelona, Huelva, Madrid, Pamplona, Salamanca, San Sebastián, Seville, Valencia

2022-12-23

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

Barcelona, Madrid, Seville

2022-12-21

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Barcelona, Madrid, Málaga, Valencia

2022-12-19

Active, closed

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

NCT05335876Spinal Muscular Atrophy (SMA)

DrugZolgensma

Novartis Pharmaceuticals

Phase 3

Barcelona

2022-12-19

Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916Breast Cancer

Greenwich LifeSciences, Inc.

Phase 3

2,250

Albacete, Alicante, Badajoz, Barcelona, Cáceres, Córdoba, El Palmar, Fuenlabrada

2022-12-16

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Santiago de Compostela, Sabadell, Barcelona, Córdoba

2022-12-16

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

213

Alcorcón, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Pozuelo de Alarcón

2022-12-15

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Barcelona, Madrid, Seville, Valencia

2022-12-15

Recruiting

Evaluation of the Functional Status of Jejunoplasty and Coloplasty and Its Impact on Quality of Life (CEREC)

NCT05802459Quality of Life, Dysphagia

Hospital Universitari de Bellvitge

Observational

Barcelona

2022-12-15

Recruiting

Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

NCT03994471End Stage Renal Disease

Iperboreal Pharma Srl

Phase 3

170

A Coruña, Badalona, Barcelona, Girona, Madrid, Oviedo

2022-12-14

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat

2022-12-14

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Barcelona, A Coruña, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia

2022-12-13

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander

2022-12-13

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

A Coruña, Badalona, Barcelona, Córdoba, Jaén, Madrid, Málaga, Sabadell

2022-12-13

Recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229Primary Mitochondrial Disease

DrugNapazimone

Pharming Technologies B.V.

Phase 2

180

Barcelona, Madrid, Valencia

2022-12-13

Active, closed

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314Carcinoma, Non-Small-Cell Lung

DrugsCapmatinib·Amivantamab

Janssen Research & Development, LLC

Phase 1/2

A Coruña, Alicante, Barcelona, Madrid, Seville, Valencia

2022-12-13

Active, closed

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT05529316Advanced Melanoma

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

150

Barcelona, Donostia / San Sebastian, Madrid, Seville, Valencia

2022-12-12

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

A Coruña, Badalona, Barakaldo, Barcelona, Castellon, Cáceres, Córdoba, Donostia / San Sebastian

2022-12-12

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Barcelona, Alicante, Las Palmas GC, Madrid, Valencia

2022-12-09

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Madrid, Badajoz, Barcelona, Cáceres, Murcia, Santiago de Compostela

2022-12-08

Active, closed

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

NCT05515536Friedreich Ataxia

DrugVatiquinone

PTC Therapeutics

Phase 3

130

Barcelona

2022-12-08

Active, closed

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

DrugOpnurasib

Novartis Pharmaceuticals

Phase 2

Barcelona, Madrid

2022-12-06

Recruiting

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

NCT05732623Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction

San Raffaele University

Observational

2,300

Barcelona

2022-12-05

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Barcelona, Madrid, Seville, Valencia

2022-12-05

Active, closed

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT05325593Primary Immune Thrombocytopenia

DrugsRomiplostim·Dexamethasone

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

129

Barcelona, Burgos, A Coruña, Granada, Madrid, Murcia, Málaga, Salamanca

2022-12-02

Active, closed

Analysising the Marginal Bone Loss, Torque and Implant Stability Placed in Bone and Tissue Level Dental Implants

NCT07288606Dental Implant, Implant Stability

University of Barcelona

Not applicable

Barcelona

2022-12-02

Recruiting

The CohorFES: a Prospective Study of Frailty and Dependence

NCT06965972Frailty Syndrome

Parc de Salut Mar

Observational

1,500

Barcelona

2022-12-01

Recruiting

Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults

NCT06621810Melanoma (Skin Cancer), Artificial Intelligence (AI), Pediatric Cancer

German Cancer Research Center

Observational

3,000

Barcelona

2022-12-01

Recruiting

The Impact of Radiotherapy on Oligometastatic Cancer

NCT05933876Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer

Institut Investigacio Sanitaria Pere Virgili

Observational

2,000

Albacete, Barcelona, Granada, Lleida, Madrid, Seville, Reus, Valencia

2022-12-01

By invitation

Cognitive Remote Assessment Using FLAME (CRA-FLAME)

NCT05624632Cognitive Impairment

Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

Observational

400

Barcelona

2022-12-01

Not yet open

Safety and Clinical Performance Study of the ARTUS® Artificial Urinary Sphincter (AUS)

NCT04827199Stress Urinary Incontinence

Myopowers Medical Technologies France SAS

Not applicable

Barcelona, Madrid

2022-12

Active, closed

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044Metastatic Colorectal Cancer

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

234

Barcelona, Madrid, Pamplona, Santander

2022-11-30

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Barcelona, Majadahonda, Murcia, Santiago de Compostela

2022-11-30

Recruiting

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

NCT05522660Non-Small Cell Lung Cancer, Melanoma

ETOP IBCSG Partners Foundation

Phase 3

180

Barcelona, Majadahonda, Valencia

2022-11-30

Recruiting

Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification

NCT06674772Headache (Migraine), Migraine, Migraine Headache, Migraine with Aura

Hospital Universitari Vall d'Hebron Research Institute

Observational

440

Barcelona

2022-11-29

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

NCT05584670Solid Tumor

DrugsSAR445877·ADG126·Zirabev·Erbitux

Sanofi

Phase 1/2

542

Barcelona, Madrid

2022-11-29

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia

2022-11-28

Active, closed

Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

NCT05659914Metastatic Pancreatic Cancer

DrugsOlaparib·Durvalumab

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 2

A Coruña, Barcelona, Santander

2022-11-28

Active, closed

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

NCT05569811Breast Cancer

DrugsPatritumab deruxtecan·Letrozole

SOLTI Breast Cancer Research Group

Phase 2

120

Badalona, Santa Cruz de Tenerife, A Coruña, Fuenlabrada, Móstoles, Badajoz, Barcelona, Bilbao

2022-11-25

Active, closed

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843Colitis Ulcerative

Sanofi

Phase 2

187

Barcelona

2022-11-25

Active, closed

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

NCT05331183Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

297

Barakaldo, Barcelona, Jerez de la Frontera, Madrid, Murcia, Sabadell, Seville, Valencia

2022-11-23

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis

DrugRamantamig

Janssen Research & Development, LLC

Phase 1

180

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-11-22

Active, closed

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 1/2

310

Barcelona, Madrid

2022-11-22

Active, closed

Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence

NCT05424484Incisional Hernia, Incisional Hernia of Midline of Abdomen, Midline Laparotomy

Medtronic - MITG

Not applicable

123

Igualada, Barcelona, Madrid, Seville

2022-11-22

Recruiting

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

NCT06708520Renal Impairment

DrugRupatadine

Noucor Health S.A.

Phase 1

Badalona, Barcelona, Madrid

2022-11-21

Recruiting

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

NCT06952452Wet Age-related Macular Degeneration

DrugsLucentis·Avastin·Bevacizumab

Parc de Salut Mar

Phase 3

630

San Cristóbal de La Laguna, Barcelona, Madrid

2022-11-18

Recruiting

Plantar Plate Repair for Treatment of Floating Toe: Must we Associate it to Weil Osteotomy?

NCT05625282Floating Toe

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

Barcelona

2022-11-18

Recruiting

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830Urothelial Carcinoma

DrugsMK-3120·Zilovertamab vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Barcelona, Madrid

2022-11-16

Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

NCT05533775Mature B-Cell Non-Hodgkin Lymphoma

DrugsIfosfamide·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

Barcelona, Madrid

2022-11-16

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Barcelona, Madrid, Málaga, Valencia

2022-11-15

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

A Coruña, Alicante, Barcelona, Madrid, Málaga, Seville, Valencia

2022-11-11

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Barcelona, Madrid, Pamplona, Seville, Tomelloso

2022-11-10

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Santiago de Compostela, Badalona, L'Hospitalet Del Llobregat, Terrassa, Santander, Barcelona, Girona, Madrid

2022-11-10

Recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

NCT05558319Newly Diagnosed Multiple Myeloma

DrugsIberdomide·Isatuximab·Bortezomib·Lenalidomide

PETHEMA Foundation

Phase 3

480

Alcalá de Henares, Pozuelo de Alarcón, Pamplona, Albacete, Badalona, Barcelona, Bilbao, Burgos

2022-11-10

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Barcelona, Madrid, Murcia, Sabadell, Seville, Valencia

2022-11-08

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville

2022-11-08

Active, closed

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure

DrugDapagliflozin

University Medical Center Groningen

Phase 3

1,750

Barcelona, Lleida, Madrid, Palma de Mallorca, Pamplona, Valencia

2022-11-08

Active, closed

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

NCT05384015Small Cell Lung Cancer Extensive Stage

DrugsLenvatinib·Etoposide·Keytruda·Carboplatin

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, A Coruña, Lugo, Madrid

2022-11-07

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

284

Pamplona, Barcelona, Madrid

2022-11-04

Active, closed

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299End-stage Renal Disease

Xeltis

Not applicable

120

Barcelona, Valencia

2022-11-04

Recruiting

+AGIL Barcelona: Integrated Care for Community-Dwelling Frail Older Adults

NCT06836167Frailty, Older Adults, Healthy Aging

Parc Sanitari Pere Virgili

Not applicable

396

Barcelona

2022-11-02

Active, closed

Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case

NCT06794281Sickle Cell Disease

Hospital Universitari Vall d'Hebron Research Institute

Observational

1,500

Barcelona

2022-11-01

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Pamplona, Barcelona, Castilleja de la Cuesta, León, Madrid, Seville

2022-11-01

Recruiting

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung

DrugAL8326

Advenchen Pharmaceuticals, LLC.

Phase 2

Barcelona, Madrid

2022-11-01

Active, closed

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055Fabry Disease

DrugMigalastat HCl

Amicus Therapeutics

Phase 3

Barcelona, Elda, Madrid

2022-10-31

Active, closed

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449Paroxysmal Nocturnal Hemoglobinuria

DrugDanicopan

Alexion Pharmaceuticals, Inc.

Phase 3

Badalona, Barcelona, Majadahonda, Seville

2022-10-28

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga

2022-10-27

Recruiting

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT05536141Clear Cell Renal Cell Carcinoma, Solid Tumors

DrugsCasdatifan·Zimberelimab·Cabozantinib·Ipilimumab

Arcus Biosciences, Inc.

Phase 1

362

Barcelona

2022-10-26

Active, closed

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial

DrugsKeytruda·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

126

Barcelona

2022-10-26

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515Non-Hodgkin Lymphoma

DrugsGolcadomide·Iberdomide·Mosunetuzumab·Glofitamab

Hoffmann-La Roche

Phase 1

121

L'Hospitalet de Llobregat, Valencia, Barcelona, Madrid, Salamanca

2022-10-26

Recruiting

The CATALINA Study

NCT05008081Chronic Obstructive Pulmonary Disease Exacerbation

Wim Janssens

Observational

1,000

Barcelona

2022-10-25

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Pozuelo de Alarcón, Salamanca

2022-10-25

Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms

DrugsPF-08046054·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

714

Barcelona, Madrid

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

L'Hospitalet de Llobregat, Barcelona, San Cristóbal de La Laguna, Alicante, Córdoba, Lleida, Madrid, Málaga

2022-10-24

Active, closed

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer

DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid

2022-10-24

Active, closed

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

NCT05387525Keratosis, Actinic

DrugDiclofenac Sodium

Almirall, S.A.

Phase 4

447

Barcelona, Granada, Madrid, Salamanca, Seville, Valencia, Zaragoza

2022-10-24

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Seville

2022-10-20

Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

NCT05547321Advanced Solid Tumor

DrugsOMTX705·Tislelizumab·Pembrolizumab

Oncomatryx Biopharma S.L.

Phase 1

150

Barcelona, L'Hospitalet de Llobregat, Santiago de Compostela, San Sebastián, Madrid, Pamplona

2022-10-20

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma

DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab

Genentech, Inc.

Phase 1

165

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2022-10-20

Active, closed

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

NCT05345171OTC Deficiency

DrugPrednisolone

Ultragenyx Pharmaceutical Inc

Phase 3

Barcelona

2022-10-18

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354Multiple Myeloma

DrugsBMS-986158·Tazemetostat·Mezigdomide·Trametinib

Bristol-Myers Squibb

Phase 1/2

260

Barcelona, Madrid, Santander

2022-10-18

Active, closed

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

NCT05620134Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer

DrugsLenvatinib Pill·Pembrolizumab

Salubris Biotherapeutics Inc

Phase 1/2

263

Barcelona, Madrid, Valencia

2022-10-17

Active, closed

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

Barcelona, Madrid

2022-10-17

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia

2022-10-14

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Santiago de Compostela, Aravaca, Barcelona, Granada, Madrid, Seville, Valencia

2022-10-14

Active, closed

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

NCT05046717Acquired Thrombotic Thrombocytopenic Purpura

Fundación Española de Hematología y Hemoterapía

Observational

500

A Coruña, Barcelona, Madrid, Valencia

2022-10-13

Recruiting

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

NCT05590715Autism Spectrum Disorder

Stalicla SA

Observational

1,500

Alicante, Barcelona, Madrid, Majadahonda, San Sebastián, Vigo

2022-10-13

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Badalona, Barcelona, El Palmar, Jerez de la Frontera, León, Madrid, Málaga, Pamplona

2022-10-13

Recruiting

Long-term Safety and Efficacy of GBG Study Participants

NCT05739591Breast Cancer

GBG Forschungs GmbH

Observational

400

Córdoba, Bilbao, Santa Cruz de Tenerife, Badalona, Barcelona, Lleida, Sabadell, Cáceres

2022-10-12

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Barcelona, Córdoba, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Majadahonda, Reus

2022-10-12

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

129

Pamplona, Barcelona, Madrid

2022-10-11

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

A Coruña, Almería, Alzira, Barcelona, Bilbao, Ferrol, Granada, León

2022-10-11

Active, closed

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

NCT05421806HIV I Infection

NEAT ID Foundation

Observational

500

Barcelona

2022-10-10

Active, closed

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases

DrugDonanemab

Eli Lilly and Company

Phase 3

1,500

Barcelona, Lleida, Sant Cugat del Vallès, Valencia

2022-10-10

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia

2022-10-04

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Barcelona, Esplugues de Llobregat, Madrid

2022-10-04

Active, closed

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903Leukemia, Myeloid, Acute

DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine

Janssen Research & Development, LLC

Phase 1

196

Barcelona, Madrid, Pamplona

2022-10-04

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

A Coruña, Alicante, Almería, Badajoz, Barcelona, Bilbao, Burgos, Cáceres

2022-10-04

Active, closed

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Barcelona

2022-10-03

Recruiting

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

NCT05537922Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

2,200

Barcelona

2022-10-01

Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

NCT05183035Acute Myeloid Leukemia

DrugsGemtuzumab Ozogamicin·Cytarabine·Azacitidine·Fludarabine

PedAL BCU, LLC

Phase 3

130

Barcelona, Madrid, Valencia

2022-10-01

Recruiting

Keeping RAASi Treatment With Optimal Potassium Control

NCT06578533Chronic Kidney Diseases

DrugSodium Zirconium Cyclosilicate

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 3

Alicante, Barcelona, Madrid, Valencia

2022-09-30

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2022-09-30

Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

NCT05476939Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered

DrugsDordaviprone·Everolimus

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

433

Barcelona, Madrid, Valencia

2022-09-29

Active, closed

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

NCT05421286HIV-1-infection, Inflammation, AIDS

Copenhagen University Hospital, Rigshospitalet

Observational

991

Badalona, Barcelona

2022-09-28

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

A Coruña, Badalona, Córdoba, Pamplona, Badajoz, Barcelona, Lleida, Madrid

2022-09-28

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Barcelona, Ferrol, Girona, Madrid, Majadahonda, Seville, Vigo, Zaragoza

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Alicante, Barcelona, Bilbao, Donostia / San Sebastian, Madrid, Seville

2022-09-23

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Barcelona, Madrid, Salamanca, Seville, Valencia

2022-09-22

Recruiting

INSIGHTFUL-FFR Clinical Trial

NCT05437900Coronary Artery Disease, Acute Coronary Syndrome

CoreAalst BV

Phase 4

2,500

Barcelona

2022-09-22

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Badalona, L'Hospitalet de Llobregat, Santander, Córdoba, Pamplona, Barcelona, Cáceres, Madrid

2022-09-20

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Palma, Barcelona, Murcia, Marbella, Cáceres, León, Madrid

2022-09-20

Active, closed

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786Sarcoma, Ewing, Neoplasm Metastasis

DrugsAbemaciclib·Temozolomide·Irinotecan

Eli Lilly and Company

Phase 2

Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia

2022-09-20

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Zaragoza

2022-09-19

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Barcelona, Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz, Vigo

2022-09-19

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

A Coruña, Barcelona, Castellon, Córdoba, Hospitalet deLlobregat, Madrid, Málaga, Ourense

2022-09-15

Recruiting

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study

NCT05562323Monkeypox

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Observational

100

Badalona, Barcelona

2022-09-14

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Badalona, Valladolid, Castellon, Alcorcón, Majadahonda, A Coruña, Barcelona, Córdoba

2022-09-13

Active, closed

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

NCT04796545AMD, Age-Related Macular Degeneration

VisionCare, Inc.

Not applicable

Alicante, Barcelona, Madrid

2022-09-13

Active, closed

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AstraZeneca

Phase 3

607

Barcelona, Palma de Mallorca

2022-09-12

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Barcelona, Madrid, Oviedo, Santander, Santiago de Compostela

2022-09-08

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab

Exelixis

Phase 3

901

Barcelona, Lleida, Madrid, Valencia, Zaragoza

2022-09-07

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville

2022-09-06

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

109

Barcelona, Granada, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Valencia, Zaragoza

2022-09-06

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Santiago de Compostela, Palma de Mallorca, L'Hospitalet de Llobregat, Málaga, Oviedo, Barcelona, Granada, Madrid

2022-09-06

Active, closed

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma

DrugSonrotoclax

BeOne Medicines

Phase 1/2

125

Barcelona, Seville

2022-09-05

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697Advanced Solid Tumors

DrugsIpilimumab·Nivolumab·Pembrolizumab

ModernaTX, Inc.

Phase 1/2

361

Logroño, Barcelona, Madrid, Málaga

2022-09-01

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Córdoba, Madrid, El Palmar, Barcelona, Pamplona, Santiago de Compostela, Valencia

2022-08-31

Active, closed

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera

Advanced Accelerator Applications

Phase 2

Barcelona

2022-08-31

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville

2022-08-30

Active, closed

Affixus Natural Nail System Humeral Nail PMCF

NCT05019664Humeral Fractures, Proximal, Humeral Fractures

Zimmer Biomet

Observational

100

Valladolid, Barcelona

2022-08-29

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Barcelona, Madrid, Valencia

2022-08-29

Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

NCT05222529Asthma

Novartis Pharmaceuticals

Phase 2

Esplugues, Sabadell, Mérida, Barcelona

2022-08-29

Active, closed

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

DrugsPemetrexed·Carboplatin

iTeos Therapeutics

Phase 2

Palma de Mallorca, Pamplona, Valencia, A Coruña, Badajoz, Barcelona, Manresa, Ourense

2022-08-26

Active, closed

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222NASH, Cirrhosis, Liver

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

845

Majadahonda, Barcelona, Madrid, Seville

2022-08-26

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Pamplona, Getxo, Barcelona, Córdoba, Lleida, Seville, Valencia

2022-08-24

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Badalona, Barcelona, Madrid

2022-08-24

Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

410

Barcelona, Madrid, Salamanca, Seville, Valladolid, Zamora, Zaragoza

2022-08-23

Active, closed

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma

DrugsAvelumab·Sacituzumab Govitecan

EMD Serono Research & Development Institute, Inc.

Phase 2

256

Badajoz, Barcelona, Córdoba, Elche, Lugo, Madrid, Manresa

2022-08-17

Recruiting

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

NCT05398679Endocarditis Infective

DrugsCefaclor·Dicloxacillin·Clindamycin·Ciprofloxacin

Fundacion Clinic per a la Recerca Biomédica

Phase 4

360

Alicante, Seville, Palma de Mallorca, Barcelona, Sabadell, Terrassa, Barakaldo, Santander

2022-08-17

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca

2022-08-17

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341HIV-1-infection

DrugsBictegravir·Lenacapavir

Gilead Sciences

Phase 2/3

689

Barcelona, Madrid, Seville

2022-08-16

Active, closed

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Janssen Research & Development, LLC

Phase 1/2

166

Barcelona, Madrid

2022-08-12

Active, closed

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883Duchenne Muscular Dystrophy (DMD)

DrugZeleciment Rostudirsen

Dyne Therapeutics

Phase 1/2

Barcelona

2022-08-12

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Barcelona, Madrid, Málaga, Pamplona, Pozuelo de Alarcón

2022-08-11

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289Lupus Nephritis

DrugIptacopan

Novartis Pharmaceuticals

Phase 2

240

Port de Sagunt, Barcelona, Ciudad Real, Madrid, Seville

2022-08-10

Active, closed

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

NCT05371080Herpes Zoster

GlaxoSmithKline

Phase 3

3,038

Balenyà (Barcelona), Barcelona, Centelles (Barcelona), La Roca del Vallès, Madrid, Majadahonda( Madrid, Marid, Peralada( Girona)

2022-08-10

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

DrugsAbraxane·Nab-paclitaxel·Gemcitabine

Panbela Therapeutics, Inc.

Phase 2/3

600

Badalona, Santander, Jaén, Barcelona, Madrid, El Palmar, Pamplona, Barakaldo

2022-08-08

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

A Coruña, Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda

2022-08-05

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Santander, Vigo, Barcelona, Córdoba, Madrid, Valencia

2022-08-04

Active, closed

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030Colorectal Cancer

DrugsM9140·Folinic acid·Adrucil·Capecitabine

EMD Serono Research & Development Institute, Inc.

Phase 1

220

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2022-08-04

Active, closed

Transanal Irrigation for Low Anterior Resection Syndrome.

NCT05245331Low Anterior Resection Syndrome

Hospital Universitari de Bellvitge

Not applicable

Barcelona, L'Hospitalet de Llobregat

2022-08-04

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

A Coruña, Barcelona, Córdoba, Madrid, Murcia, Valencia

2022-08-03

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Badajoz, Badalona, Barcelona, Córdoba, Girona, Madrid, Majadahonda, Málaga

2022-08-03

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Barcelona

2022-08-03

Active, closed

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

466

Barcelona, Madrid, Málaga, Pontevedra, Valencia, Zaragoza

2022-08-03

Recruiting

Perpetual Observational Study - Ventilator Associated Pneumonia

NCT05719259Ventilator Associated Pneumonia

European Clinical Research Alliance for Infectious Diseases (ECRAID)

Observational

20,000

Córdoba, Oviedo, Burjassot, Barcelona

2022-08-03

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Barcelona, Madrid, Valencia

2022-08-03

Active, closed

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

NCT05133531Paroxysmal Nocturnal Hemoglobinuria

DrugsSoliris·Ultomiris·Cemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Bilbao, Barcelona, Murcia, Salamanca

2022-08-01

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595Advanced or Metastatic Colorectal Cancer

DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan

Janssen Research & Development, LLC

Phase 1/2

225

Barcelona, Madrid, Santander, Valencia

2022-07-29

Active, closed

Noninterventional Study Evaluating Parkinson's Disease Diary Use

NCT05363046Parkinson's Disease

BlueRock Therapeutics

Observational

194

Santurtzi, Barcelona, Pontevedra, Seville, Valencia

2022-07-29

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Málaga, Murcia, Santa Cruz de Tenerife

2022-07-25

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Pamplona, Santander, Seville

2022-07-22

Active, closed

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613Mucopolysaccharidosis II

DrugsIdursulfase·Tividenofusp alfa

Denali Therapeutics Inc.

Phase 2/3

Barcelona, Madrid

2022-07-21

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

L'Hospitalet Del Llobregat, Barcelona, Madrid, Pamplona, Salamanca

2022-07-21

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Murcia, Seville, Valencia

2022-07-20

Recruiting

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

NCT05451784Metastatic Triple-Negative Breast Carcinoma

DrugSerplulimab

Fundacio Clinic Barcelona

Phase 1/2

Barcelona, Madrid, Pamplona

2022-07-20

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Sant Andreu de la Barca, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Granada, Huelva, Madrid, Málaga

2022-07-18

Active, closed

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Phase 1/2

Barcelona, Madrid

2022-07-18

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid

2022-07-14

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Barcelona, Granada, Pamplona, Zaragoza

2022-07-14

Active, closed

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,546

Córdoba, Badalona, Barcelona, Donostia / San Sebastian, El Palmar, Oviedo, A Coruña, Girona

2022-07-14

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Barcelona, Madrid, Seville, Valencia

2022-07-13

Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma

DrugDibotatug

Dren Bio

Phase 1/2

200

Barcelona, Salamanca

2022-07-13

Active, closed

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696Extensive Stage Small Cell Lung Cancer

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera·Atezolizumab

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid, Málaga

2022-07-13

By invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827Age Related Macular Degeneration (AMD)

Gyroscope Therapeutics Limited

Phase 2

225

Barcelona, Madrid, Pamplona

2022-07-12

Active, closed

ADHD Remote Technology Study of Cardiometabolic Risk Factors and Medication Adherence

NCT05301673Attention Deficit Hyperactivity Disorder, Cardiovascular Diseases, Medication Adherence

King's College London

Observational

600

Barcelona

2022-07-12

Active, closed

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446Metastatic Colorectal Cancer

DrugsEncorafenib·Erbitux·Cetuximab·Keytruda

Pfizer

Phase 2

108

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza

2022-07-11

Active, closed

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446Coronary Artery Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

610

A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2022-07-08

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville

2022-07-08

Active, closed

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

NCT04936282Kidney Transplant Failure and Rejection

DrugGrafalon

Fundación Canaria Instituto de Investigación Sanitaria de Canarias

Phase 4

Barcelona, Málaga, Santa Cruz de Tenerife

2022-07-05

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Barcelona, Madrid, Santander

2022-07-05

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Binimetinib·Encorafenib·Zirabev

Pfizer

Phase 4

210

A Coruña, Badalona, Barcelona, Santander, Lleida, Majadahonda, Madrid, Málaga

2022-07-05

Active, closed

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733Biliary Atresia

DrugOdevixibat

Albireo, an Ipsen Company

Phase 3

180

Barcelona

2022-07-05

Active, closed

CREST-2 Long-term Observational Extension Study

NCT05465122Stenoses, Carotid

Mayo Clinic

Observational

2,480

Barcelona

2022-07-05

Recruiting

European Rare Blood Disorders Platform (ENROL)

NCT06250595Anemia, Bone Marrow Failure, Bleeding Disorder, Iron Metabolism Disorders

Hospital Universitari Vall d'Hebron Research Institute

Observational

37,090

Barcelona

2022-07-01

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Barcelona, Madrid, Valencia

2022-06-30

Recruiting

International Wilson's Disease Patient Registry (iWilson Registry)

NCT05239858Wilson's Disease

Orphalan

Observational

500

Las Palmas de Gran Canaria, Barcelona, Seville, Valencia

2022-06-29

Active, closed

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

237

Barcelona, Madrid, Toledo

2022-06-27

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594Advanced Solid Malignancies

DrugsPalacaparib·Dato-DXd·Trastuzumab deruxtecan·Temozolomide

AstraZeneca

Phase 1/2

695

A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Seville

2022-06-24

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Pamplona, Barcelona, Cáceres, Córdoba, Madrid, Málaga, Murcia, Oviedo

2022-06-23

Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis

CytoSorbents, Inc

Observational

3,000

Barcelona, Huelva

2022-06-22

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Barcelona, Granada, Madrid, Santander, Valencia

2022-06-21

Active, closed

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

NCT05181618Severe Hemophilia A, Moderate Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 4

136

A Coruña, Barcelona, Madrid, Málaga

2022-06-20

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189Non-Small Cell Lung Cancer

DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib

BioNTech SE

Phase 1

320

Badalona, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2022-06-17

Active, closed

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma

DrugsLoncastuximab Tesirine·Mosunetuzumab·Polatuzumab Vedotin·Glofitamab

ADC Therapeutics S.A.

Phase 1

154

Barcelona, Madrid, Salamanca, Valencia

2022-06-17

Active, closed

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment

Fundación GECP

Observational

100

A Coruña, Alicante, Badalona, Barcelona, Bilbao, Córdoba, Girona, Pamplona

2022-06-17

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia

2022-06-16

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2022-06-14

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142Clear Cell Renal Cell Carcinoma

Xencor, Inc.

Phase 1

307

Barcelona, Madrid

2022-06-13

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Castellon, Santander, Seville, Barcelona

2022-06-10

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

A Coruña, Barcelona, Madrid

2022-06-09

Active, closed

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710Transplant Rejection

DrugsAntithymocyte globulin·Riliprubart·Immunoglobulin·IVIG

Sanofi

Phase 2

Barcelona, Madrid

2022-06-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

NCT05144256Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2022-06-08

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

Pamplona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2022-06-08

Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

DrugsASP2138·Ramucirumab·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 1

398

Barcelona, El Palmar, Zaragoza

2022-06-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2022-06-06

Recruiting

Neck Evolution With Ovation in Spain

NCT05823519Abdominal Aortic Aneurysm

DGM Vascular

Observational

120

Palma de Mallorca, Girona, Barakaldo, Burgos, Salamanca, Toledo, Gijón, Barcelona

2022-06-01

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

NCT05413421Metastatic Prostate Cancer

DrugsDarolutamide (Nubeqa)·Rinzimetostat·Apalutamide (Erleada)

ORIC Pharmaceuticals

Phase 1

275

Barcelona, Madrid

2022-06-01

Recruiting

Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

NCT05673681Melanoma

Fundación Academia Española de Dermatología

Observational

7,000

Badalona, A Coruña, Barcelona, Córdoba, Las Palmas, León, Madrid, Oviedo

2022-06-01

Recruiting

Comparative Study Between the Use of Trapeziometacarpal Prostheses and the Usual Resection-tenosuspension Arthroplasty for the Treatment of Rhizarthrosis, Focusing on Changes in Pain (Measured With the VAS Scale) and Function (With the Quick-DASH).

NCT07101887Rizarthrosis

Parc de Salut Mar

Not applicable

Barcelona

2022-06-01

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Almería, Barcelona, Córdoba, Madrid, Majadahonda, Seville

2022-05-30

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Rincón de la Victoria, Santiago de Compostela

2022-05-30

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

312

Barcelona, Leganés, Madrid, Moncloa-Aravaca, Pozuelo de Alarcón, Usera, Pamplona, Valencia

2022-05-25

Recruiting

Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry.

NCT05128604Endoscopic Surgical Procedure, Safety, Training

Hospital Universitari de Bellvitge

Observational

Badalona, L'Hospitalet de Llobregat, Terrassa, Barcelona, Girona

2022-05-23

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2022-05-23

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Barcelona, Las Palmas de Gran Canaria, Madrid, Toledo, Valencia

2022-05-22

Active, closed

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703Relapsing-remitting Multiple Sclerosis

DrugsFingolimod·Ocrelizumab

Hoffmann-La Roche

Phase 3

188

Esplugues de Llobregas, Barcelona, Madrid, Seville

2022-05-19

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Seville, A Coruña, Barcelona, Madrid, Málaga, Oviedo, Pamplona, Valencia

2022-05-17

Active, closed

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257Limited-Stage Small Cell Lung Cancer

DrugsCarboplatin/cisplatin-etoposide·Serplulimab

Shanghai Henlius Biotech

Phase 3

511

Badajoz, Badalona, Barcelona, Córdoba, Madrid, Seville, Valdecilla, Valencia

2022-05-17

Recruiting

Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure

NCT05641662Cardiovascular Diseases

Linkoeping University

Not applicable

750

Barcelona, Manresa, Valencia

2022-05-16

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville

2022-05-16

Recruiting

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705Breast Cancer

DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 1

260

Barcelona, Madrid, Pozuelo de Alarcón, Valencia

2022-05-11

Recruiting

Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence

NCT04976153Fecal Incontinence

Innovacell GmbH

Phase 3

290

Barcelona, Mataró, Murcia, Oviedo

2022-05-11

Recruiting

Effect of Radiofrequency in Women With Chronic Pelvic Pain With an Associated Myofascial Syndrome Versus Myofascial Therapy and no Treatment

NCT06908200Chronic Pelvic Pain

Hospital Clinic of Barcelona

Not applicable

Barcelona

2022-05-10

Active, closed

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728Glioblastoma

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera

Novartis Pharmaceuticals

Phase 1

Granada, Barcelona, Madrid

2022-05-10

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Sabadell, Barcelona, Madrid, Seville

2022-05-03

Active, closed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746Breast Cancer Stage II

DrugRibociclib

SOLTI Breast Cancer Research Group

Phase 2

1,100

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, León, Madrid, Salamanca

2022-05-03

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Majadahonda, Bilbao, Barcelona, Madrid, Málaga

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Badalona, L'Hospitalet de Llobregat, El Palmar, Barcelona, Córdoba, Madrid, Málaga, Valencia

2022-05-02

Active, closed

Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease

NCT05192616Angioplasty, Peripheral Arterial Disease, Iliac Artery Disease, Covered Stent

iVascular S.L.U.

Observational

241

Barcelona, Bilbao, Sabadell

2022-04-27

Active, closed

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755Moderate Aortic Valve Stenosis

Medtronic Cardiovascular

Not applicable

650

Barcelona, Madrid, Salamanca, Valladolid

2022-04-27

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Pamplona, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2022-04-26

Active, closed

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

NCT05346224Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer

DrugPertuzumab

Shanghai Henlius Biotech

Phase 3

900

Santiago de Compostela, Barcelona

2022-04-25

Recruiting

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

NCT05114850Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure

P+F Products + Features GmbH

Observational

450

Galdakao, Málaga, Barcelona, Córdoba, Lugo, Madrid, Oviedo, Salamanca

2022-04-20

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

NCT04916613Prostate Cancer Metastatic

DrugDarolutamide

UNICANCER

Phase 3

300

Badalona, Barcelona, Girona, Madrid, Manresa, Valencia

2022-04-19

Active, closed

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348Multiple Myeloma

DrugsElotuzumab·Selinexor·Pomalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

117

Barcelona, Gijón, Girona, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-04-19

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Barcelona, Girona, Madrid, Marbella, Santiago de Compostela, Valencia

2022-04-19

Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

NCT04685616Hodgkin Lymphoma

DrugsVinblastine·Filgrastim·Pegfilgrastim·Bleomycin

University College, London

Phase 3

1,042

Barcelona, Pamplona

2022-04-14

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

A Coruña, Alicante, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Reus

2022-04-14

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Barcelona, El Palmar, Madrid, Santiago de Compostela, Seville, Zaragoza

2022-04-14

Recruiting

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT05356741Locally Advanced or Metastatic HER2-Expressing Cancers

DrugsKeytruda·Pembrolizumab

Vir Biotechnology, Inc.

Phase 1/2

645

Madrid, Barcelona, Pamplona, Pozuelo de Alarcón

2022-04-13

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Barcelona, Gijón, Madrid

2022-04-13

Active, closed

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155Non-Muscle Invasive Bladder Neoplasms

DrugErdafitinib

Janssen Research & Development, LLC

Phase 1/2

235

Barcelona, Córdoba, Madrid, Valencia

2022-04-11

Recruiting

Zimmer® Natural Nail® (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study

NCT05022485Tibial Fractures, Fracture Infection

Zimmer Biomet

Observational

500

Barcelona

2022-04-11

By invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2/3

600

Barcelona, Córdoba, Ellenboro, Madrid, Seville

2022-04-05

Active, closed

Registry of Pediatric Orthopedic Trauma and Health Outcomes in Skeletally Immature Children

NCT04207892Long Bone Fractures

AO Innovation Translation Center

Observational

1,000

Barcelona, Valladolid

2022-04-05

Recruiting

The Effect of the Movement Imitation Therapy in Preterm (MIT-PB) in Motor Behavior's Quality.

NCT05319158Premature Birth, Risk, Early Intervention

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Not applicable

Barcelona, Sabadell, Girona

2022-04-04

Active, closed

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Barcelona, Madrid, Valencia, Zaragoza

2022-04-01

Recruiting

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615Autoimmune Encephalitis, Encephalitis

DrugsUplizna·Inebilizumab

University of Utah

Phase 2

116

Barcelona

2022-03-30

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879Proteinuric Kidney Disease

Vertex Pharmaceuticals Incorporated

Phase 2/3

466

Barcelona, Córdoba, Madrid, Seville

2022-03-30

Active, closed

Tissue Level vs Bone Level Implants for Plural Restorations : a Multicentre Randomised Controlled Trial

NCT05223387Dental Implants, Edentulous

Anthogyr

Not applicable

Barcelona, Santiago de Compostela

2022-03-30

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Barcelona, Madrid, Oviedo, Málaga, Valencia, Zaragoza

2022-03-29

Recruiting

Smartwatch and External Holter Monitoring to Detect Atrial Fibrillation in Patients With Cryptogenic Stroke

NCT05565781Paroxysmal Atrial Fibrillation, Cryptogenic Stroke

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

100

Barcelona

2022-03-28

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville

2022-03-28

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Lenvatinib·Durvalumab

AstraZeneca

Phase 3

760

Barcelona, Córdoba, Donostia / San Sebastian, Madrid

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Barcelona, Córdoba, Lugo, Madrid, Málaga, Sabadell, Seville

2022-03-25

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Ávila, Barcelona, Jaén, Madrid, Valencia

2022-03-25

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Barcelona, El Palmar, Granada, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Santiago de Compostela, Barcelona, L'Hospitalet Del Llobregat, Terrassa, Badalona, Salamanca, Pozuelo de Alarcón, Madrid

2022-03-25

Active, closed

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors

DrugsRYZ101·Octreotide·Lanreotide·Sunitinib

RayzeBio, Inc.

Phase 3

343

Barcelona, Madrid, Zaragoza

2022-03-24

Active, closed

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559Haemophilia A and B With and Without Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

153

El Palmar, Barcelona, Madrid, Málaga

2022-03-24

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Madrid, Málaga, Barcelona, Seville

2022-03-24

Recruiting

Validation of a microRNA-based Fecal (miRFec) Test for Colorectal Cancer Screening, Surveillance and Diagnosis

NCT05346757Colorectal Cancer

Fundacion Clinic per a la Recerca Biomédica

Not applicable

5,390

Barcelona

2022-03-23

Active, closed

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

NCT04980222Lymphoma

DrugsGlofitamab·Tocilizumab·Vincristine·Doxorubicin

Hoffmann-La Roche

Phase 2

Barcelona, Madrid, Salamanca

2022-03-22

Active, closed

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051Neoplasms

DrugsRemzistotug·GSK5764227·Nelistotug·Belrestotug

GlaxoSmithKline

Phase 1

152

Barcelona, Madrid, Málaga

2022-03-22

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094Non-small Cell Lung Cancer Stage III, KRAS P.G12C

DrugSotorasib

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, Granada, Jaén, A Coruña

2022-03-21

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553Active Juvenile Psoriatic Arthritis

DrugApremilast

Amgen

Phase 3

San Cristóbal de La Laguna, Barcelona, Esplugues de Llobregat, Valencia, Madrid

2022-03-17

Active, closed

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease

Diagram B.V.

Not applicable

1,223

Barcelona, Madrid, Santander, Valencia

2022-03-16

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Girona, Madrid, Valencia, Barcelona, Lugo, Málaga

2022-03-15

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Ferrol, Madrid, Santander

2022-03-15

Active, closed

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400Breast Cancer, Solid Tumors

DrugsPF-07104091·Atirmociclib

Pfizer

Phase 1/2

235

Barcelona, Madrid, Seville

2022-03-14

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

A Coruña, Palma, Barcelona, El Palmar, Málaga, Pamplona, Reus, Valencia

2022-03-11

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700Solid Tumors

ORIC Pharmaceuticals

Phase 1/2

350

Barcelona, Madrid

2022-03-10

Active, closed

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma

DrugTislelizumab

HiFiBiO Therapeutics

Phase 1

Barcelona, Madrid, Valencia

2022-03-10

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2022-03-09

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Barcelona, Madrid, Santiago de Compostela

2022-03-08

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab

Hoffmann-La Roche

Phase 1

332

Barcelona

2022-03-07

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Málaga, Palma de Mallorca, EI Palmar, Barcelona, Cáceres, Madrid, Valencia, La Laguna Tenerife

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza

2022-03-04

Active, closed

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382Alzheimer Disease

DrugFlorbetaben

Tharick Pascoal

Phase 1

822

Barcelona

2022-03-02

Active, closed

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

UroGen Pharma Ltd.

Phase 3

240

Barcelona, Bilbao, Madrid

2022-03-01

Recruiting

Single cEll pRofiling PErsistaNce To ImmuNothErapy

NCT06680739Colorectal Cancer, Endometrial Cancer

DrugsTremelimumab·Durvalumab

Vall d'Hebron Institute of Oncology

Phase 2

Barcelona

2022-03-01

Active, closed

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973Amyloidosis

DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

151

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-03-01

Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax

Sumitomo Pharma America, Inc.

Phase 1/2

606

Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander

2022-02-28

Recruiting

Efficacy of Simvastatin in Alcoholic Liver Fibrosis

NCT04971577Liver Fibrosis, Alcohol Abuse

DrugSimvastatin

Anna Cruceta

Phase 2/3

Barcelona

2022-02-22

Active, closed

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

NCT05051033Mitral Valve Regurgitation

Annetine Gelijns

Not applicable

450

Palma de Mallorca, Vigo, Barcelona, Madrid, Oviedo

2022-02-21

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Barcelona, Málaga, Valencia, Vigo, Zaragoza

2022-02-21

Active, closed

Clinical Impact of the IBox As an Early Intervention TooL

NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications

Predict4Health

Not applicable

507

Barcelona, Valencia

2022-02-18

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2

310

Barcelona, Madrid, Murcia, Valencia

2022-02-17

Recruiting

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

NCT05263206Pruritus

DrugsFexofenadine·Dupilumab

Sanofi

Phase 3

284

Barcelona, Pontevedra, Alicante, Córdoba

2022-02-15

Active, closed

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

NCT05121376Hereditary Angioedema, HAE

BioMarin Pharmaceutical

Phase 1/2

Barcelona, Madrid

2022-02-15

Active, closed

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

NCT04573023Mucopolysaccharidosis II

DrugsIdursulfase·JR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Barcelona

2022-02-14

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

A Coruña, Alicante, Almería, Barcelona, Córdoba, Granada, Madrid, Málaga

2022-02-07

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2022-02-07

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2022-02-03

Active, closed

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

113

Barcelona, Madrid, Málaga, Murcia, Seville

2022-02-02

Recruiting

Physiological Pacing for AV Block to Prevent Pacemaker-induced Cardiomyopathy

NCT05214365Conduction System Pacing, Conventional Ventricular Pacing

Hospital Clinic of Barcelona

Not applicable

200

Barcelona

2022-02-01

Recruiting

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

NCT05183984Ovarian Cancer

DrugsBevacizumab-awwb·Niraparib

ARCAGY/ GINECO GROUP

Phase 2

390

A Coruña, Barcelona, Cáceres, El Palmar, Murcia, Jerez de la Frontera, Madrid, Málaga, Oviedo

2022-02-01

Active, closed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

NCT05262023Frontotemporal Dementia

Denali Therapeutics Inc.

Phase 1/2

Barcelona, Donostia / San Sebastian, Seville

2022-02-01

Active, closed

TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT04561986Antibody-mediated Rejection

DrugTocilizumab

Vastra Gotaland Region

Phase 3

A Coruña, Barcelona, Valencia

2022-02-01

Recruiting

BIOmarkers and PLAtelet Function Assessment in Myocardial Ischemia and Non Obstructive Coronary Arteries Study

NCT05714241Ischemia With no Obstructive Coronary Artery Disease

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

200

Barcelona

2022-02-01

Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC

DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin

Synthekine

Phase 1/2

364

Barcelona, Logroño, Madrid, Málaga, Pamplona

2022-01-25

Active, closed

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases

Quell Therapeutics Limited

Phase 1/2

Barcelona, Córdoba, Madrid

2022-01-21

Active, closed

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668Neurofibromatosis Type 1

DrugSelumetinib

AstraZeneca

Phase 1/2

Barcelona, Madrid

2022-01-21

Recruiting

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Not applicable

608

Alcalá de Henares, Barcelona, Granada, Madrid, Salamanca, Seville, Valladolid

2022-01-18

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Alicante, Badalona, Barcelona, Córdoba, Lugo, Madrid, Santander, Zaragoza

2022-01-15

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Santiago de Compostela, L'Hospitalet de Llobregat, Córdoba, Las Palmas de Gran Canaria, Majadahonda, Barcelona, Madrid

2022-01-13

Recruiting

The "Global Paradise System" Registry

NCT05027685Hypertension

ReCor Medical, Inc.

Observational

3,000

Barcelona, Madrid

2022-01-13

Active, closed

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer

DrugsTrastuzumab emtansine·Trastuzumab·Pembrolizumab

Ascendis Pharma Oncology Division A/S

Phase 1/2

320

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Seville

2022-01-11

Recruiting

National GMA Post-market Clinical Follow-up Study (GRACE)

NCT05636709Crohn Disease, Ulcerative Colitis

Adacyte Therapeutics SL

Observational

350

Albacete, Alicante, Badalona, Barcelona, Galdakao, Castellon, Cadiz, Córdoba

2022-01-11

Active, closed

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634Partial Epilepsy

SK Life Science, Inc.

Phase 3

140

Barcelona, Madrid, Seville

2022-01-10

Recruiting

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

NCT05363657Kidney Cancer

Azienda Ospedaliero-Universitaria Careggi

Observational

10,000

Barcelona, Madrid

2022-01-10

Active, closed

Time-Restricted Feeding in Children and Adolescents With Obesity

NCT05174871Obesity, Childhood, Obesity, Adolescent

Fundació Sant Joan de Déu

Not applicable

Barcelona

2022-01-04

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

A Coruña, Barcelona, Madrid

2022-01-04

Active, closed

Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III

NCT07821333Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell

DrugsFolfoxiri·Folfox

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 2

L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Valencia

2022-01-01

Recruiting

Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research

NCT05398380Colorectal Cancer, Liver Metastases, Genetic Change

Hospital Vall d'Hebron

Not applicable

Barcelona

2022-01-01

Recruiting

Efficacy of the Use of Diaries in Intensive Care Units

NCT05288140Diary (Blank Journal), Intensive Care Unit, Patient, Family

University of Barcelona

Not applicable

240

Barcelona

2022-01-01

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Manises, Barcelona, Granada, Madrid

2021-12-28

Active, closed

Lorlatinib Continuation Study

NCT05144997Non-Small-Cell Lung Cancer, NSCLC

DrugLorlatinib

Pfizer

Phase 4

Barcelona

2021-12-28

Active, closed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394Alzheimers Disease, Dementia, Alzheimers Disease, Familial

DrugsE2814·Lecanemab

Washington University School of Medicine

Phase 2/3

197

Barcelona

2021-12-22

Active, closed

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590Alzheimer Disease, Early Onset, Mild Cognitive Impairment

DrugsDasatinib·Ribociclib

Washington University School of Medicine

Phase 2

Barcelona, Seville

2021-12-22

Active, closed

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226Neuroendocrine Tumors

DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin

ITM Solucin GmbH

Phase 3

259

Barcelona, Madrid, Oviedo, Santiago de Compostela, Valencia

2021-12-21

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

194

Barcelona, Madrid, Murcia, Seville

2021-12-20

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Santiago de Compostela, Cadiz, Córdoba, Badalona, Barcelona, L'Hospitalet Del Llobregat, Mataró, León

2021-12-20

Active, closed

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627Relapsed Multiple Myeloma

DrugsBelantamab mafodotin·Carfilzomib·Dexamethasone

PETHEMA Foundation

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Palma de Mallorca, Pamplona

2021-12-20

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Badajoz, Pozuelo de Alarcón, Oviedo, A Coruña, Barcelona, Madrid, Málaga, Zaragoza

2021-12-17

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Madrid, Barcelona

2021-12-17

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

NCT05147220Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,000

Cadiz, Seville, Barcelona, Sant Joan Despí, Salt, Alcorcón, Getafe, Majadahonda

2021-12-16

Recruiting

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda

Phase 2

135

Badalona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2021-12-16

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugDecitabine

Taiho Oncology, Inc.

Phase 1

Barcelona, La Rioja, Lleida, Madrid, Murcia, Valencia

2021-12-15

By invitation

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases

DrugsKITE-197·SPRX002·KITE-753·Tecartus

Kite, A Gilead Company

Observational

1,500

Barcelona, Salamanca

2021-12-15

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia

2021-12-14

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

Barcelona, Valencia

2021-12-14

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Santiago Compostela, Vitoria-Gasteiz, L'Hospitalet de Llobregat, Albacete, Barcelona, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz

2021-12-13

Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC

NCT05167487Stage IIIA Non-small Cell Lung Cancer

DrugsParaplatin·Cisplatin·Carboplatin

Fundación GECP

Observational

150

A Coruña, Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda

2021-12-13

Active, closed

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals

Observational

207

Santa Cruz de Tenerife, Barcelona, Las Palmas

2021-12-13

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona

2021-12-10

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

Badalona, Barcelona, Madrid, Majadahonda, Pamplona

2021-12-10

Active, closed

EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

NCT05029414Acute Ischemic Stroke

University Hospital, Basel, Switzerland

Not applicable

543

Barcelona, Girona, Madrid, Murcia, Valladolid

2021-12-09

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Barcelona, Valencia, Madrid

2021-12-08

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2021-12-07

Active, closed

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugRilzabrutinib

Sanofi

Phase 2

Barakaldo, Barcelona, Madrid, Seville

2021-12-07

Active, closed

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

NCT03496883Intracerebral Hemorrhage

DrugRecombinant Factor VIIa

Joseph Broderick, MD

Phase 3

860

Badalona, Horta, L'Hospitalet de Llobregat, Barcelona, Girona, Lleida

2021-12-03

Active, closed

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT05177835Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 2

203

Barcelona

2021-12-03

Recruiting

Spanish Wilson Disease Registry

NCT06466291Wilson Disease

Asociación Española para el Estudio del Hígado

Observational

600

Barcelona

2021-12-02

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Sabadell, Pamplona, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga

2021-12-02

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

Vigo, Barcelona, Madrid, Seville, Valencia

2021-12-01

Recruiting

International Survey of Acute Coronavirus Syndromes-COVID-19

NCT05188612COVID-19

University of Bologna

Observational

10,000

Barcelona

2021-12-01

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Málaga, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Valencia, Madrid

2021-12-01

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

258

Barcelona, Madrid, Murcia, Seville

2021-11-30

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Barcelona, Madrid, Toledo

2021-11-30

Recruiting

RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

NCT06213402Sickle Cell Disease, Thalassemia, Hemolytic; Anemia, Hereditary, Due to Enzyme Disorder, Anemia Due to Membrane Defect

Hospital Universitari Vall d'Hebron Research Institute

Observational

32,564

Barcelona

2021-11-30

Active, closed

PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.

NCT04963179Asherman Syndrome, Intrauterine Adhesion

Womed

Not applicable

160

Barcelona, Madrid

2021-11-29

Recruiting

Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

NCT05146440Advanced Soft-tissue Sarcoma, Advanced L-sarcomas, Other Advanced Sarcomas, Advanced Solid Tumor

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2

195

Zaragoza, Barcelona, Madrid

2021-11-23

Recruiting

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

NCT04743765Hip Fractures, Myocardial Injury

Population Health Research Institute

Not applicable

1,100

Barcelona, Sabadell, Sant Pere de Ribes, Terrassa, Marbella, Valladolid, Madrid

2021-11-22

Active, closed

Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction

NCT03849586Erectile Dysfunction

European Association of Urology Research Foundation

Observational

1,076

Barcelona, Boadilla del Monte, Madrid, Majadahonda, Móstoles, Palma de Mallorca, Santander

2021-11-19

Active, closed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT05130450Familial Chylomicronemia Syndrome

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid, Seville

2021-11-18

Active, closed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Small-Cell Lung Cancer

DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab

Hoffmann-La Roche

Phase 3

660

A Coruña, Barcelona, Madrid, Málaga, Seville

2021-11-18

Active, closed

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

NCT05012254Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer

DrugsYervoy·Paraplatin·Taxol·Ipilimumab

Fundación GECP

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Castellon, Las Palmas de Gran Canaria, Jaén, A Coruña, León

2021-11-18

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

300

Barcelona, Gijón, Granada, Jerez de la Frontera, León, Madrid, Palma, Pamplona

2021-11-18

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

A Coruña, Badalona, Barakaldo, Barcelona, Cáceres, Girona, Madrid, Málaga

2021-11-17

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

245

A Coruña, Barcelona, Madrid, Zaragoza

2021-11-17

Active, closed

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

NCT05081557Atopic Dermatitis

AbbVie

Observational

873

Badalona, Barcelona, L'Hospitalet de Llobregat, Terrassa, Granada, Huelva, Jaén, Logroño

2021-11-17

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-11-17

Recruiting

Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

NCT04973397Preoperative Care, Surgery--Complications, Myocardial Infarction

Centre hospitalier de l'Université de Montréal (CHUM)

Observational

15,000

Barcelona

2021-11-17

Recruiting

The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent

NCT04923191Coronary Artery Disease

National University of Ireland, Galway, Ireland

Not applicable

2,540

Barcelona, Lugo, Valladolid, Vigo

2021-11-12

Active, closed

Clinical Trial With Artiflex Presbyopic (Artiplus)

NCT04632784Presbyopia, Ametropia, Refractive Errors, Myopia

Ophtec BV

Not applicable

Bilbao, Barcelona, Madrid, Seville

2021-11-12

Recruiting

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

NCT04924868Acute Pancreatitis Due to Gallstones

DrugUrsodeoxycholic Acid

Hospital General Universitario de Alicante

Phase 3

332

Santiago de Compostela, Alicante, Elche, Barcelona, L'Hospitalet de Llobregat, Sabadell, Santander, Granada

2021-11-10

Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

140

Barcelona, Madrid

2021-11-09

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

A Coruña, Badalona, Barcelona, Santiago de Compostela

2021-11-07

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia

2021-11-02

Active, closed

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

NCT05112237Cardiomyopathy

Tenaya Therapeutics

Observational

200

Barcelona, Madrid, Vigo

2021-11-01

Recruiting

Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery

NCT04754022Disorder, Heart, Postoperative, Cardiac Surgery

Unity Health Toronto

Not applicable

1,440

Barcelona, Valencia

2021-11-01

Active, closed

Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice

NCT04899141Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

400

Málaga, Barakaldo, Barcelona, Cáceres, Ciudad Real, Donostia / San Sebastian, Elche, Galdakao

2021-10-29

Active, closed

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05117476Advanced Solid Tumor, NSCLC

DrugsCLN-619·Carboplatin (AUC 6)·Dato-DXd·Pemetrexed

Cullinan Therapeutics Inc.

Phase 1

440

Las Palmas de Gran Canaria, Barcelona, Madrid, Pamplona, Sabadell

2021-10-29

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-10-28

Recruiting

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

NCT05141474Epithelial Tumors, Malignant, Malignant Solid Tumor

DrugsAldesleukin·Fludarabine·Cyclophosphamide

Vall d'Hebron Institute of Oncology

Early Phase 1

Barcelona

2021-10-28

Active, closed

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

GWT-TUD GmbH

Phase 3

Badalona, Barcelona, Madrid, Oviedo, Salamanca, Valencia

2021-10-27

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296Systemic Lupus Erythematosus

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

303

Barcelona, Madrid

2021-10-26

Active, closed

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

DrugsHerzuma·Perjeta·Herceptin·Adriamycin

AstraZeneca

Phase 3

927

Barcelona, Madrid, Seville, Vigo

2021-10-25

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

400

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-10-25

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Tecentriq

Hoffmann-La Roche

Phase 1

542

Donostia / San Sebastian, Majadahonda, Barcelona, Madrid, Valencia, Zaragoza

2021-10-22

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

A Coruña, Barcelona, Elche, Girona, Madrid, Málaga, Murcia, Oviedo

2021-10-22

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

A Coruña, Barcelona, Seville

2021-10-22

Active, closed

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT04857372Mesothelioma

Novartis Pharmaceuticals

Phase 1

137

Barcelona

2021-10-21

Active, closed

Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)

NCT05082454Aortic Valve Disease

JOTEC GmbH

Observational

108

Badalona, Barcelona

2021-10-20

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Badalona, Barcelona, Madrid, Pamplona

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-10-18

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Barcelona, Gijón, Las Palmas de Gran Canaria, Madrid, Palma, Pamplona, Pozuelo de Alarcón, Salamanca

2021-10-14

Active, closed

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 3

123

Barcelona, Madrid

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville

2021-10-13

Active, closed

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

NCT04884282Metastatic Non Small Cell Lung Cancer

DrugsTedopi·Docetaxel·Nivolumab

Fondazione Ricerca Traslazionale

Phase 2

105

A Coruña, Barcelona, Madrid, Mataró, Málaga

2021-10-12

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Santander, A Coruña, Barcelona, Madrid, Seville

2021-10-11

Active, closed

Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms

W.L.Gore & Associates

Observational

614

Barcelona, Vigo

2021-10-09

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

NCT05011123Yellow Fever

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

690

Barcelona, L'Hospitalet de Llobregat, Madrid

2021-10-07

Active, closed

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342Ovarian Cancer

DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 2

176

Barcelona, Madrid, Málaga

2021-10-07

Recruiting

MYTHS - MYocarditis THerapy With Steroids

NCT05150704Myocarditis Acute

DrugMethylprednisolone

Niguarda Hospital

Phase 3

288

A Coruña, Barcelona, Madrid, Málaga, Murcia

2021-10-07

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Granada, El Palmar, Pamplona, Barcelona, Madrid

2021-10-06

Active, closed

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence

DrugsOxaliplatine·Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2

Barcelona, Madrid, Santander, Valencia

2021-10-05

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Santiago de Compostela, L'Hospitalet Del Llobregat, Terrassa, Santander, Pamplona, Toledo, Barcelona, Girona

2021-10-04

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville

2021-10-04

Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies

NCT05093153Waldenstrom Macroglobulinemia

Fundación Española de Hematología y Hemoterapía

Observational

1,000

Mérida, Palma, Palma de Mallorca, Badalona, Barcelona, Manresa, Sabadell, Córdoba

2021-10-01

Active, closed

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807Carcinoma, Non-Small-Cell Lung

DrugsEntrectinib·Crizotinib

Hoffmann-La Roche

Phase 3

217

A Coruña, Barcelona, Madrid, Málaga

2021-09-30

Active, closed

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer

DrugsCMP 001·Utomilumab·Talazoparib·Axitinib

Pfizer

Phase 3

Barcelona, L'Hospitalet de Llobregat, Madrid, Seville

2021-09-29

Active, closed

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer

DrugSabestomig

AstraZeneca

Phase 1/2

136

Barcelona, Madrid

2021-09-28

Active, closed

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

NCT04884815Wilson Disease

Ultragenyx Pharmaceutical Inc

Phase 1/2

Barcelona

2021-09-27

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-09-23

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Madrid, Oviedo, Barcelona, Seville

2021-09-23

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Barcelona, Madrid, Seville, Zaragoza

2021-09-22

Active, closed

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

NCT04850105Hereditary Transthyretin Amyloidosis With Polyneuropthy

Akcea Therapeutics

Observational

202

Huelva, Oviedo, Palma de Mallorca, Villarreal, Barcelona, Madrid

2021-09-21

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Barcelona, Madrid, Majadahonda, Marbella, Oviedo, Pozuelo de Alarcón, Seville, Toledo

2021-09-20

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Pamplona, Barcelona, Salamanca

2021-09-20

Active, closed

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

NCT04888312Metastatic Pancreatic Ductal Adenocarcinoma

DrugMitazalimab

Alligator Bioscience AB

Phase 1/2

Barcelona, Madrid, Seville, Zaragoza

2021-09-17

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605Relapsed/Refractory Multiple Myeloma

DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab

BeOne Medicines

Phase 1/2

246

Barcelona

2021-09-16

Active, closed

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035Lymphoma, B-Cell

DrugsGolcadomide·Iberdomide·Polatuzumab Vedotin·Prednisolone

Celgene

Phase 1

224

Barcelona, Málaga, Salamanca

2021-09-15

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Elche, Badalona, Barcelona, Madrid

2021-09-15

Active, closed

A Multi-Center Post-Market Data Collection Protocol to Evaluate the Performance of Orthofix Spine Devices

NCT05082090Spinal Disorders/Injuries

Orthofix Inc.

Observational

2,000

Barcelona, Palma de Mallorca, Santander

2021-09-15

Active, closed

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523Non-Small-Cell Lung Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

212

Barcelona, Madrid

2021-09-14

Active, closed

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

NCT05063786Advanced Breast Cancer

DrugsAlpelisib·Herceptin·Eribulin·Vinorelbine

Spanish Breast Cancer Research Group

Phase 3

A Coruña, Albacete, Alicante, Badajoz, Badalona, Barcelona, Bilbao, Cadiz

2021-09-14

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Barcelona, Madrid, Majadahonda, Valencia

2021-09-13

Active, closed

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059Non-small Cell Lung Cancer

DrugCarboplatin

AstraZeneca

Phase 3

Alicante, Barcelona, Córdoba, León, Madrid, Málaga, Murcia, Oviedo

2021-09-12

Active, closed

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163Solid Tumors, KRAS Mutation

DrugsBI 1701963·Midazolam

Boehringer Ingelheim

Phase 1

Barcelona

2021-09-09

Recruiting

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

NCT04528082Behçet Disease

DrugApremilast

Amgen

Phase 3

Seville, Barcelona, Esplugues de Llobregat, Valencia, Madrid

2021-09-09

Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer

Guardant Health, Inc.

Observational

2,285

A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela

2021-09-07

Active, closed

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811Non Small Cell Lung Cancer

DrugTaletrectinib

Nuvation Bio Inc.

Phase 2

217

Barcelona, Madrid, Málaga, Seville, Valencia

2021-09-01

Active, closed

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

NCT04827953Pancreatic Ductal Adenocarcinoma

DrugsNLM-001·Zalifrelimab·Nab-paclitaxel·Gemcitabine

Nelum Corp

Phase 1/2

Santiago de Compostela, Málaga, Zaragoza, Donostia / San Sebastian, Barcelona, Santander

2021-09-01

Active, closed

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282Desmoid, Desmoid Tumor

Immunome, Inc.

Phase 2/3

198

Barcelona, Madrid, Zaragoza

2021-09-01

Active, closed

Biology-Driven Cognitive Profiling in Huntington's Disease

NCT07503743Huntington's Disease (HD)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2021-09-01

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Madrid, Málaga, Sabadell

2021-08-30

Recruiting

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer

DrugsKeytruda·Pembrolizumab

Medicenna Therapeutics, Inc.

Phase 1/2

115

Badalona, Barcelona, Madrid, Oviedo, Torrejón

2021-08-27

Recruiting

A Registry Study on HIV-related Lymphoma

NCT05231135AIDS Related Lymphoma, HIV Related Lymphoma

Rotkreuzklinikum München gGmbH

Observational

300

Barcelona, Salamanca

2021-08-25

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

A Coruña, Algeciras / Cadiz, Barcelona, Bilbao, Córdoba, Granada, Madrid, Oviedo

2021-08-25

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Almería, Badalona, Palma de Mallorca, Barcelona, Sabadell, León, Madrid, Majadahonda

2021-08-19

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville

2021-08-19

Active, closed

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817Small Cell Lung Carcinoma

DrugsMK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab·R-DXd

Merck Sharp & Dohme LLC

Phase 1/2

110

L'Hospitalet de Llobregat, Barcelona

2021-08-19

Active, closed

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

NCT05007782Advanced Solid Tumor

DrugsDenikitug·Zimberelimab

Gilead Sciences

Phase 1

304

Barcelona, Madrid, Pamplona

2021-08-18

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT04844866Diffuse Large B-cell Lymphoma

Miltenyi Biomedicine GmbH

Phase 2

213

Barcelona, Madrid, Murcia, Pamplona, Salamanca

2021-08-18

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Badalona, Santiago de Compostela, Madrid, Oviedo, Barcelona

2021-08-18

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

NCT04629833Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 3

210

Badalona, Barcelona, Madrid, Málaga, Valencia

2021-08-16

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Almería, Badalona, Barcelona, Boadilla del Monte, Córdoba, El Palmar, Fuencarral-El Pardo, Huelva

2021-08-14

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Madrid, Oviedo, Barcelona

2021-08-12

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis

DrugSparsentan

Travere Therapeutics, Inc.

Phase 2

Barcelona, Madrid, Seville

2021-08-12

Active, closed

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

DrugsChidamide·Nivolumab

HUYABIO International, LLC.

Phase 3

450

Barcelona, Madrid, Málaga, Seville, Zaragoza

2021-08-12

Active, closed

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

NCT05704361Multiple Sclerosis

Hoffmann-La Roche

Phase 1

119

Barcelona

2021-08-11

Active, closed

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975EPP, XLP

Tanabe Pharma America, Inc.

Phase 3

286

Barcelona, Madrid, Valencia

2021-08-10

Recruiting

Effect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery

NCT04926597Malnutrition

Philipp Schuetz

Not applicable

1,200

Barcelona, Getafe, León, Madrid, Málaga, Valladolid

2021-08-05

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville

2021-08-05

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona?page=5

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,238 of those studies with a site in Barcelona.

How many clinical trials are recruiting in Barcelona?

1,669 of the 3,238 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 132 have not yet opened recruitment, 1,365 are active but closed to new participants, and 72 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.